Literature DB >> 27978570

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.

Nicole M Kuderer1, Kimberly A Burton1, Sibel Blau2, Andrea L Rose2, Stephanie Parker2, Gary H Lyman3, C Anthony Blau4.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 27978570      PMCID： PMC5824236          DOI： 10.1001/jamaoncol.2016.4983

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

2.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

3.  Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.

Authors:  Glen J Weiss; Brandi R Hoff; Robert P Whitehead; Ashish Sangal; Susan A Gingrich; Robert J Penny; David W Mallery; Scott M Morris; Eric J Thompson; David M Loesch; Vivek Khemka
Journal:  Onco Targets Ther       Date:  2015-04-24       Impact factor: 4.147

4.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.

Authors:  Richard B Lanman; Stefanie A Mortimer; Oliver A Zill; Dragan Sebisanovic; Rene Lopez; Sibel Blau; Eric A Collisson; Stephen G Divers; Dave S B Hoon; E Scott Kopetz; Jeeyun Lee; Petros G Nikolinakos; Arthur M Baca; Bahram G Kermani; Helmy Eltoukhy; AmirAli Talasaz
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

5.  Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.

Authors:  Young Kwang Chae; Andrew A Davis; Benedito A Carneiro; Sunandana Chandra; Nisha Mohindra; Aparna Kalyan; Jason Kaplan; Maria Matsangou; Sachin Pai; Ricardo Costa; Borko Jovanovic; Massimo Cristofanilli; Leonidas C Platanias; Francis J Giles
Journal:  Oncotarget       Date:  2016-10-04

6.  Comparing two assays for clinical genomic profiling: the devil is in the data.

Authors:  Rachel M Squillace; Garrett M Frampton; Phil J Stephens; Jeffrey S Ross; Vincent A Miller
Journal:  Onco Targets Ther       Date:  2015-08-24       Impact factor: 4.147
  6 in total
  61 in total

1.  Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.

Authors:  Rohan Gupta; Tamer Othman; Chen Chen; Jaideep Sandhu; Ching Ouyang; Marwan Fakih
Journal:  Oncologist       Date:  2019-11-19

2.  Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2018-09-06       Impact factor: 54.908

Review 3.  Liquid Biopsy to Identify Actionable Genomic Alterations.

Authors:  Sai-Hong Ignatius Ou; Misako Nagasaka; Viola W Zhu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 4.  Liquid biopsies in lung cancer-time to implement research technologies in routine care?

Authors:  Linda Köhn; Mikael Johansson; Kjell Grankvist; Jonas Nilsson
Journal:  Ann Transl Med       Date:  2017-07

5.  Towards a comprehensive framework for cell-free DNA analysis: lessons from TRACERx.

Authors:  Bryan C Ulrich; Nicolas Guibert
Journal:  Ann Transl Med       Date:  2017-11

6.  Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.

Authors:  Rohan Gupta; Tamer Othman; Chen Chen; Jaideep Sandhu; Ching Ouyang; Marwan Fakih
Journal:  Oncologist       Date:  2019-11-18

Review 7.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

8.  Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.

Authors:  Zhong Ye; Chun Wang; Shaogui Wan; Zhaomei Mu; Zhenchao Zhang; Maysa M Abu-Khalaf; Frederick M Fellin; Daniel P Silver; Manish Neupane; Rebecca J Jaslow; Saveri Bhattacharya; Theodore N Tsangaris; Inna Chervoneva; Adam Berger; Laura Austin; Juan P Palazzo; Ronald E Myers; Neha Pancholy; Darayus Toorkey; Kaelan Yao; Max Krall; Xiuling Li; Xiaobing Chen; Xiuhong Fu; Jinliang Xing; Lifang Hou; Qiang Wei; Bingshan Li; Massimo Cristofanilli; Hushan Yang
Journal:  Eur J Cancer       Date:  2018-12-04       Impact factor: 9.162

9.  [Centralized molecular tumor diagnostics by commercial providers : Consequences for patients, patient care, and research].

Authors:  P Schirmacher; A Stenzinger; T Kirchner
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

10.  Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.

Authors:  Vincent Bernard; Dong U Kim; F Anthony San Lucas; Jonathan Castillo; Kelvin Allenson; Feven C Mulu; Bret M Stephens; Jonathan Huang; Alexander Semaan; Paola A Guerrero; Nabiollah Kamyabi; Jun Zhao; Mark W Hurd; Eugene J Koay; Cullen M Taniguchi; Joseph M Herman; Milind Javle; Robert Wolff; Matthew Katz; Gauri Varadhachary; Anirban Maitra; Hector A Alvarez
Journal:  Gastroenterology       Date:  2018-09-19       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.